These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34162728)

  • 1. Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
    Montresor A; Toffali L; Fumagalli L; Constantin G; Rigo A; Ferrarini I; Vinante F; Laudanna C
    J Immunol; 2021 Jul; 207(2):671-684. PubMed ID: 34162728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
    Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
    Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia.
    Montresor A; Toffali L; Mirenda M; Rigo A; Vinante F; Laudanna C
    Oncotarget; 2015 Oct; 6(33):34245-57. PubMed ID: 26413812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein tyrosine phosphatase receptor type γ is a JAK phosphatase and negatively regulates leukocyte integrin activation.
    Mirenda M; Toffali L; Montresor A; Scardoni G; Sorio C; Laudanna C
    J Immunol; 2015 Mar; 194(5):2168-79. PubMed ID: 25624455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
    Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
    Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
    Tissino E; Benedetti D; Herman SEM; Ten Hacken E; Ahn IE; Chaffee KG; Rossi FM; Dal Bo M; Bulian P; Bomben R; Bayer E; Härzschel A; Gutjahr JC; Postorino M; Santinelli E; Ayed A; Zaja F; Chiarenza A; Pozzato G; Chigaev A; Sklar LA; Burger JA; Ferrajoli A; Shanafelt TD; Wiestner A; Del Poeta G; Hartmann TN; Gattei V; Zucchetto A
    J Exp Med; 2018 Feb; 215(2):681-697. PubMed ID: 29301866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
    de Rooij MF; Kuil A; Geest CR; Eldering E; Chang BY; Buggy JJ; Pals ST; Spaargaren M
    Blood; 2012 Mar; 119(11):2590-4. PubMed ID: 22279054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia.
    Chen SS; Chiorazzi N
    Hematol Oncol; 2023 Jun; 41 Suppl 1():119-128. PubMed ID: 37294973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR/Integrin Interaction in CLL: A Physiologic Remnant with Clinical Relevance.
    Tissino E; Bomben R; Gattei V; Zucchetto A
    Clin Cancer Res; 2023 Sep; 29(18):3560-3562. PubMed ID: 37439706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.
    Sharif-Askari B; Doyon D; Paliouras M; Aloyz R
    Sci Rep; 2019 Jul; 9(1):11069. PubMed ID: 31363127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
    Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
    Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
    Chen R; Tsai J; Thompson PA; Chen Y; Xiong P; Liu C; Burrows F; Sivina M; Burger JA; Keating MJ; Wierda WG; Plunkett W
    Blood Cancer J; 2021 Mar; 11(3):57. PubMed ID: 33714981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.
    Herman SE; Mustafa RZ; Jones J; Wong DH; Farooqui M; Wiestner A
    Clin Cancer Res; 2015 Oct; 21(20):4642-51. PubMed ID: 26089373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.